Vaccines: latest news

Vaccines resources

  • Vaccines

    HIV vaccine researchers are still looking for a vaccine that would offer a significant degree of protection against HIV infection....

    From: Preventing HIV

    Information level Level 4
  • Vaccines

    The promise of an effective HIV vaccine has always been just over the horizon, but more than 20 years after the identification of HIV, vaccines...

    From: HIV transmission & testing

    Information level Level 4

Vaccines features

Vaccines news from aidsmap

More news

Vaccines news selected from other sources

  • Healthy competition intensifies 30-year quest for HIV vaccine

    By funding two similar projects at once, the EU aims to inspire a sense of friendly competition between them. But the programmes share researchers and conduct complementary work, careful not to duplicate their efforts. Both Prof. Shattock and Prof. Pantaleo say that either European team would be happy if the other found a vaccine that worked.

    21 May 2018 | Horizon magazine
  • Inovio HIV Vaccine, Which Generated Near 100% Immune Responses, Sustained Durable Memory Responses Measured One Year After The Start of Clinical Trial

    Inovio Pharmaceuticals, Inc. today announced that its HIV vaccine, PENNVAX®-GP, maintained durable and robust immune responses at month 12, a full six months after the last dose in a Phase 1 clinical study. Inovio previously reported that PENNVAX-GP elicited the highest overall levels of immune response rates (cellular and humoral) ever demonstrated in a human study by an HIV vaccine.

    16 May 2018 | Inovio press release
  • Genetically Altered Broadly Neutralizing Antibodies Protect Monkeys from HIV-Like Virus

    Single infusions of each modified bNAb protected two groups of six monkeys each against weekly exposures to simian-human immunodeficiency virus (SHIV) for up to 37 weeks, compared with a median of 3 weeks in 12 monkeys receiving no antibody.

    16 April 2018 | NIAID press release
  • Zambia, South Africa prevention study finds those with herpes virus facing six times HIV risk

    Communities’ HIV prevalence could be predicted “almost exactly” from prevalence of herpes virus, researchers find.

    14 April 2018 | Science Speaks
  • Call to extend HPV vaccine to boys as cancer rates soar

    NHS England urged to act after new figures reveal rising head and neck tumours in men: Health officials will soon come under increasing pressure to extend vaccination against the cancer-causing human papilloma virus to young men. Doctors say new figures, to be released in a few weeks, will show that rates of head and neck cancers in men are now rising so quickly that it is imperative the policy is reversed. “To be blunt, the case for giving the vaccine to boys as well as girls is now unequivocal as far as I am concerned,” said Professor Mark Lawler, of Queen’s University Belfast. “We have a chance to eradicate both these conditions – cervical as well as neck and head cancers – and we should not be hesitating.”

    01 April 2018 | The Guardian
  • Better ways to combat HIV than seeking a vaccine

    Are human-vaccine trials the best use of resources? Based on the current reality, HIV treatment and prevention strategies that have been proven to work would be a much better use of the millions of dollars being spent on the large-scale vaccine clinical trials.

    22 March 2018 | Business Day
  • Big improvements in HIV vaccine production

    Technical advances in vaccine production should shorten the time to clinical trials, breaking the logjam of promising new candidate vaccines waiting to be tested.

    06 February 2018 | Science Daily
  • Setting the Standard: New prevention trials in the era of oral PrEP

    There’s a lot going on in the world of HIV prevention research right now. One key issue is how participants might access oral PrEP as part of HIV prevention trials. It may seem simple: trial participants have the right to the highest standard of HIV prevention and care as part of participation. But the ethics, trial design issues and the mechanisms by which interventions are provided as standard of care are quite complex. Opinions differ and politics abound.

    08 December 2017 | AVAC
  • Johnson & Johnson and Partners Announce First Efficacy Study for Investigational Mosaic HIV-1 Preventive Vaccine

    The new, large-scale study (HVTN 705/HPX2008), also known as “Imbokodo”, will evaluate whether the investigational Janssen vaccine regimen is safe and able to reduce the incidence of HIV infection among 2,600 women in sub-Saharan Africa.

    30 November 2017 | Johnson & Johnson press release
  • Four big insights into HIV/AIDS that provide hope of finding a vaccine

    African researchers have been performing cutting-edge research to contribute to addressing the HIV epidemic. The sub-Saharan African Network for TB/HIV Research Excellence has been at the forefront of this research and has provided some important insights into how the virus spreads as well as the immune mechanisms that enable some people to control the virus without antiretroviral drugs.

    24 November 2017 | The Conversation
More news

Our information levels explained

  • Short and simple introductions to key HIV topics, sometimes illustrated with pictures.
  • Expands on the previous level, but also written in easy-to-understand plain language.
  • More detailed information, likely to include medical and scientific language.
  • Detailed, comprehensive information, using medical and specialised language.
Community Consensus Statement on Access to HIV Treatment and its Use for Prevention

Together, we can make it happen

We can end HIV soon if people have equal access to HIV drugs as treatment and as PrEP, and have free choice over whether to take them.

Launched today, the Community Consensus Statement is a basic set of principles aimed at making sure that happens.

The Community Consensus Statement is a joint initiative of AVAC, EATG, MSMGF, GNP+, HIV i-Base, the International HIV/AIDS Alliance, ITPC and NAM/aidsmap
close

This content was checked for accuracy at the time it was written. It may have been superseded by more recent developments. NAM recommends checking whether this is the most current information when making decisions that may affect your health.

NAM’s information is intended to support, rather than replace, consultation with a healthcare professional. Talk to your doctor or another member of your healthcare team for advice tailored to your situation.